Optimi Health Corp. (OPTH) Stock Price & Analysis
Optimi Health Corp. (OPTH) closed at USD 3.19 on Thursday, October 15, 2026, up 0.79% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.17; the Oct 15, 2026 session ranged USD 3.05–3.44 on volume of 34,813 shares. Market capitalization is $18.27M, with a 52-week range of USD 3.04–6.4 (NCM). Source: Nexqual, retrieved October 16, 2026 at 07:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OPTH.md
Key facts (OPTH)
- Analysts: None.
- Total return with dividends: 1Y -47.5% vs S&P 500 +18.1%; 5Y -45.5% vs S&P 500 +85.1%.
Analysts (OPTH)
Consensus None.
Total return (dividends reinvested) (OPTH)
| 1Y (from 2026-05-20) | 5Y (from 2026-05-18) | |
|---|---|---|
| Total return | -47.5% | -45.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 88.9% | 78.2% |
| Max drawdown | -47.9% (May 2026→Oct 2026) | -46.6% (May 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 07:24 UTC)
| Price | USD 3.19 |
|---|---|
| Change | ▲ 0.79% (up) |
| Previous Close | USD 3.17 |
| Open | USD 3.24 |
| Day Range | USD 3.05 – 3.44 |
| 52-Week Range | USD 3.04 – 6.4 |
| Volume | 34,813 shares |
| Market Cap | $18.27M |
| Exchange | NCM |
Technical Analysis (OPTH)
Nexqual's technical model rates OPTH "SELL" based on 2 bullish and 5 bearish signals across 103 daily candles, as of October 16, 2026 at 07:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 18.99 (oversold) |
| vs SMA50 | Below (USD 4.64) |
| MACD | -0.38 (negative) |
Analyst Ratings (OPTH)
Wall Street analysts rate OPTH "None", per Nexqual as of October 16, 2026 at 07:24 UTC.
| Consensus Rating | None |
|---|
Earnings (OPTH)
| Revenue Estimate | $270,000 |
|---|
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Financials & Fundamentals (OPTH)
| Total Revenue | $175,671 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -28.60% |
| Gross Margin | -175.41% |
| Operating Margin | -957.82% |
| Profit Margin | +0.00% |
| ROE | -54.36% |
| Debt / Equity | 0.29 |
| Current Ratio | 1.73 |
| Total Cash | $13.07M |
| Total Debt | $5.14M |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Financial Health Score (OPTH)
Nexqual rates Optimi Health Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 07:24 UTC.
| Growth | Critical — Revenue -29% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — CAD 13M cash vs CAD 5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -CAD 5M (TTM) |
| Efficiency | Critical — ROE -54%, ROA -16.1% |
Ownership (OPTH)
| Insider Ownership | +12.66% |
|---|---|
| Institutional Ownership | +7.29% |
| Shares Outstanding | 5.73M |
| Float | 4.65M |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Leadership (OPTH)
Optimi Health Corp. is led by Dane Stevens (age 36), Co-Founder, CEO, Corporate Secretary & Director, per Nexqual as of October 16, 2026 at 07:24 UTC.
| Co-Founder, CEO, Corporate Secretary & Director | Dane Stevens (age 36) |
|---|---|
| Co-Founder & Chairman | John James Wilson (age 36) |
| Co-Founder, COO & Director | Bryan Edward Safarik (age 40) |
| Interim CFO & Director | Jacob Safarik (age 37) |
| Chief Strategy Officer | Robert Martin |
Major Backers & Investors (OPTH)
Notable institutional backers of Optimi Health Corp. include AdvisorShares Trust-AdvisorShares Psychedelics ETF, Yorkville Advisors Global, LP, Mariner, LLC, according to Nexqual as of October 16, 2026 at 07:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 4.55% |
| Yorkville Advisors Global, LP | 3.48% |
| Mariner, LLC | 2.14% |
| AdvisorShares Investments, LLC | 1.8% |
| Two Sigma Securities, LLC | 0.19% |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 07:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt